# Study of PF-07248144 in Advanced or Metastatic Solid Tumors

> **NCT04606446** · PHASE2 · RECRUITING · sponsor: **Pfizer** · enrollment: 320 (estimated)

## Conditions studied

- Locally Advanced or Metastatic ER+ HER2- Breast Cancer
- Locally Advanced or Metastatic Castration-resistant Prostate Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** PF-07248144
- **DRUG:** Fulvestrant
- **DRUG:** Letrozole
- **DRUG:** Palbociclib
- **DRUG:** PF-07220060
- **DRUG:** PF-07850327, ARV-471, vepdegestrant

## Key facts

- **NCT ID:** NCT04606446
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-16
- **Primary completion:** 2029-07-13
- **Final completion:** 2029-08-10
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04606446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04606446, "Study of PF-07248144 in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04606446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*